Table of Contents
GAL-INT-6 The safety and efficacy of galantamine in patients with Vascular dementia or AD with cerebrovascular disease Sean Lilienfeld MD, FCP, MMed Janssen Research Foundation
Interactions between vascular dementia and Alzheimer’s disease
Reminyl in vascular and mixed dementia: trial inclusion criteria
Inclusion Criteria Probable Vascular Dementia (NINDS-AIREN)
Inclusion Criteria Probable Vascular Dementia (NINDS-AIREN)
Inclusion Criteria Probable Vascular Dementia (NINDS-AIREN)
Inclusion Criteria Mixed Dementia (Possible AD with CVD)
Inclusion Criteria Mixed Dementia (Possible AD with CVD)
Exclusion Criteria
NINDS-AIREN Radiology
Patient characteristics
ADAS-cog Scores: Placebo patients Over 6 Months
ADAS-cog Scores: Placebo patients Over 6 Months
NPI Scores: Placebo patients Over 6 Months
NPI Scores: Placebo patients Over 6 Months
DAD Scores: Placebo patients Over 6 Months
DAD Scores: Placebo patients Over 6 Months
Efficacy results
Conclusions
Conclusions
Galantamine Significantly Improved Both Primary Endpoints and Both Secondary Endpoints
|